From January 2019 to June 2020, five patients with advanced NSCLC with HER2 alterations and chemo-immunotherapy as the first-line treatment were admitted to the Lung Cancer Center, West China Hospital, Sichuan University. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.